Henry Schein, Inc. $HSIC Shares Bought by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 21.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 218,340 shares of the company’s stock after buying an additional 39,188 shares during the quarter. Alliancebernstein L.P. owned approximately 0.18% of Henry Schein worth $14,954,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Investment Management Corp VA ADV purchased a new stake in shares of Henry Schein in the fourth quarter valued at about $32,000. Rakuten Securities Inc. acquired a new stake in shares of Henry Schein during the first quarter worth $34,000. Whittier Trust Co. lifted its stake in shares of Henry Schein by 714.3% in the 1st quarter. Whittier Trust Co. now owns 798 shares of the company’s stock worth $55,000 after acquiring an additional 700 shares during the period. Quarry LP purchased a new position in shares of Henry Schein during the 1st quarter worth approximately $71,000. Finally, UMB Bank n.a. grew its holdings in Henry Schein by 23.2% during the first quarter. UMB Bank n.a. now owns 1,066 shares of the company’s stock worth $73,000 after acquiring an additional 201 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HSIC has been the topic of a number of recent analyst reports. UBS Group lowered their price target on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Stifel Nicolaus reissued a “hold” rating and issued a $75.00 price objective (down from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. JPMorgan Chase & Co. reduced their target price on Henry Schein from $80.00 to $76.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Leerink Partners set a $75.00 price objective on Henry Schein in a research report on Monday, July 14th. Finally, Baird R W downgraded shares of Henry Schein from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 14th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $76.67.

Henry Schein Trading Up 3.2%

NASDAQ HSIC opened at $69.55 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49. The company’s fifty day moving average price is $69.44 and its two-hundred day moving average price is $69.53. The company has a market capitalization of $8.43 billion, a price-to-earnings ratio of 22.44, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). The firm had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.